SCHEMBL434948

SCHEMBL434948

OCCn1cnnc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2473112 0.82
SCHEMBL15568358 0.79 MEN1 (0.33)
SCHEMBL10706339 0.71 LMNA (0.37)
SCHEMBL4505762 0.69
SCHEMBL7358339 0.67
Bromide SCHEMBL30865617 0.67
Hydrochloric Acid SCHEMBL6437681 0.66
SCHEMBL14969311 0.65
SCHEMBL467081 0.65
SCHEMBL333508 0.61

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114105511-B Corrosion-resistant gas-phase rust inhibitor, preparation method thereof and gas-phase rust-resistant film box 国网电子商务有限公司 2022-12-27 CN claimed
CN-114105511-A Corrosion-resistant gas-phase rust inhibitor, preparation method thereof and gas-phase rust-resistant film box 国网电子商务有限公司 2022-03-01 CN claimed
EP-0842988-A1 Spin-transition chemical compounds and temperature threshold crossing display devices comprising an active medium which contains at least one of those compounds DE LA RUE CARTES ET SYSTEMES (FR) 1998-05-20 EP claimed
EP-4103559-B1 HETEROCYCLIC PAD4 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2026-03-04 EP disclosed
US-12473304-B2 Heterocyclic PAD4 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2025-11-18 US disclosed
WO-2025149545-A1 HETEROARYLPHENYL ETHER DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2025-07-17 WO disclosed
US-20250197368-A1 2-OXO-DIHYDROQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS GABA TYPE A RECEPTOR MODULATORS DRAIG THERAPEUTICS LTD. (GB) 2025-06-19 US disclosed
CN-115348961-B Heterocyclic PAD4 inhibitors 百时美施贵宝公司 2025-03-04 CN disclosed
WO-2023215220-A1 MACROCYCLIC INHIBITORS OF ATP CITRATE LYASE ESPERION THERAPEUTICS, INC. (US) 2023-11-09 WO disclosed
CN-116472042-A 2-oxo-dihydroquinoline-3-carboxamide derivatives as modulators of GABA A type receptors 加的夫大学学院咨询有限公司 2023-07-21 CN disclosed
US-20230167131-A1 HETEROCYCLIC PAD4 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2023-06-01 US disclosed
EP-0873319-B1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2001-07-25 EP disclosed
US-6258951-B1 ANTICANCER, ANTIARTHRITIC AGENTS ZENECA LIMITED (GB) 2001-07-10 US disclosed
WO-2000047212-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2000-08-17 WO disclosed
US-6071921-A Chemical compounds ZENECA LIMITED (GB) 2000-06-06 US disclosed
US-5962458-A ANGIOGENESIS INHIBITORS, ANTICANCER AGENTS, ANTIDIABETIC AGENTS, SKIN DISORDERS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS, VISION DEFECTS ZENECA LIMITED (GB) 1999-10-05 US disclosed
CN-1205694-A Quinazoline derivatives ZENECA LTD (GB) 1999-01-20 CN disclosed
EP-0873319-A1 QUINAZOLINE DERIVATIVES ZENECA LIMITED (GB) 1998-10-28 EP disclosed
EP-0842988-A1 Spin-transition chemical compounds and temperature threshold crossing display devices comprising an active medium which contains at least one of those compounds DE LA RUE CARTES ET SYSTEMES (FR) 1998-05-20 EP disclosed
WO-1997022596-A1 QUINAZOLINE DERIVATIVES ZENECA LIMITED (GB) 1997-06-26 WO disclosed